PWE-044 The IBD bioresource: progressing from genetics to function and clinical translation in CD & UC. (8th June 2018)

• Record Type: Journal Article
• Authors: Pele, Laetitia; Simpkins, Rachel; Thorbinson, Catherine; Francis, Deepthy; Lewis, Sophie; Shawky, Rasha; Parkes, Miles
• Is Part Of: Gut. Volume 67(2018)Supplement 1
• Page Start: A89
• Page End: A89
• Publication Date: 2018-06-08
• Subjects: Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2018-BSGAbstracts.176
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Introduction: The Inflammatory Bowel Disease (IBD) BioResource was established by the UK IBD Genetics Consortium and the NIHR BioResource in 2016 to expedite the clinical translation of recent genetics advances and support important IBD research. It recruits patients from hospitals UK-wide, the aim being to enlist 25 000 participants who can be further invited for future research studies based on genotype and/or phenotype. DNA samples will also be used in on-going IBD genetics analyses by the UK IBD Genetics Consortium. Methods: The Main cohort comprises individuals with established Crohn's Disease (CD) and Ulcerative Colitis (UC). Both clinical and self-reported phenotype data are collected, alongside plasma, serum and DNA samples for whole Genome Sequencing. The Inception cohort aims to recruit a sub-set of 1000 individuals newly diagnosed with IBD that will provide more detailed sampling, unconfounded by drug treatment or effects of surgery and includes stool, biopsy tissue and whole blood for RNA. This cohort offers a unique resource to undertake transcriptomic, meta-genomic, metabolomic and proteomic studies and facilitate research into determinants, predictors and biomarkers of IBD disease course and treatment response. In addition to Stage 1 recruitment, the IBD BioResource panel can be accessed by any researchers (both academic and commercial) with ethically approved proposals and may involve a range of possible options, such as access to data or samples or recall of genotype-selected participants to donate further samples or trial novel therapies. Results: 24 months in, we have 59 hospitals active and ~30 in set-up. Main Cohort: over 8000 patients have been recruited – CD/UC 4, 390/3, 832. CD phenotypes: extent – 31% ileal, 32% ileo-colonic, 31% colonic, 28% with peri-anal involvement; behaviour – 68% inflammatory, 21% stenosing and 11% penetrating. 5048 (61%) have been prescribed thiopurines and 2324 (28%) required treatment cessation. 3842 (47%) have received anti-TNFα therapy. 45% CD and 5% UC have required surgery. Most subjects are recruited in medical gastroenterology clinics so there are biases in this dataset. We will provide updates and breakdown of numbers at the meeting and discuss downstream stage 2 studies. Inception Cohort: has been launched and is being rolled out nationally. Conclusion: The IBD BioResource and its network are on course to generate an accessible platform of patients and their data that will facilitate high quality translational IBD research.